Sharing-our-perspective-page-header2



Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward


  • Florida Enacts Opioid Prescribing Restrictions

    by
    • Optum Workers' Comp
    | Mar 22, 2018
    Tag Icon
    Workers' Compensation, Opioids
    On March 19 the Florida Governor signed into law, legislation containing numerous provisions aimed at curbing and controlling the opioid crisis in Florida. This legislation, House Bill 21, includes several provisions called for, and supported by the Governor since efforts to address opioids failed in 2017, and is seen as a first step for Florida against the opioid scourge.


  • Safety concerns regarding sterile compounded products from Cantrell Drug Company

    by
    • Optum Workers' Comp
    | Mar 14, 2018
    Tag Icon
    Workers' Compensation, recall, FDA, Compounded Medications
    The U.S. Food and Drug Administration (FDA) issued a warning to health care professionals and is urging consumers to stop using sterile products, including opioid products and other medications intended for sterile injection, produced by Cantrell Drug Company in Little Rock, Arkansas. According to the FDA, they are “concerned about serious deficiencies in Cantrell’s compounding operations, including its processes to ensure quality and sterility assurance that put patient safety at risk.” If compounded injectable products are not sterile and are prepared in non-sterile environments, administering the medications to patients can result in serious, possibly life-threatening infections.


  • WCRC contractor transition webinar held with The Centers for Medicare and Medicaid Services

    by
    • Optum Workers' Comp
    | Mar 08, 2018
    Tag Icon
    Webinar - Workers' Compensation, Workers' Compensation, WCRC, Webinar, MSA, CMS
    The Centers for Medicare and Medicaid Services (CMS) held a webinar, March 7, 2018, to introduce Capitol Bridge LLC, our new WCRC contractor and review the transition plan.


  • FDA approves Apadaz™ - new short-acting opioid analgesic for acute pain

    by
    • Optum Workers' Comp
    | Mar 01, 2018
    Tag Icon
    Opioids, FDA
    KemPharm, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Apadaz (benzhydrocodone and acetaminophen), an immediate-release (short-acting) opioid analgesic combination product. Apadaz is intended for the short-term (no more than 14 days) management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.


  • Arizona Joins States Enacting Opioid Prescribing Restrictions

    by
    • Optum Workers' Comp
    | Feb 22, 2018
    Tag Icon
    Opioids
    Arizona’s Governor recently signed into law Senate Bill 1001 which, among other changes, establishes several new requirements for prescribing and dispensing opioids. Most notably, Arizona has gone the route of several other states over the last couple of years by enacting days’ supply and morphine milligram equivalent (MME) limits on prescriptions for these medications.


  • Purdue no longer promoting OxyContin® to doctors

    by
    • Optum Workers' Comp
    | Feb 13, 2018
    Tag Icon
    Opioids
    Purdue Pharma LP announced it will no longer actively promote OxyContin® to doctors. Following its launch in 1996, Purdue marketed the pain medication to doctors to prescribe for patients with pain. In workers’ compensation, OxyContin has been one of the most widely prescribed and highest ranked long-acting opioid analgesic in terms of medication spend in the past decade.


  • Localized shortages of Nucynta® products reported

    by
    • Optum Workers' Comp
    | Feb 05, 2018
    Tag Icon
    Opioids
    Following the devastation and power outages in Puerto Rico from Hurricane Maria, Depomed issued a press release indicating there may be temporary delays in the packaging and delivery of Nucynta® ER (tapentadol extended-release). Certain dosage strengths are being manufactured by the company’s third-party partner located on the island and those dosages would be potentially affected. The company reported that it did not expect any disruption to the supply of the immediate-release (IR) formulation of Nucynta.



Stay informed by receiving latest updates

Do you have a question about a blog post?